Medical Developments International Limited (MVP) AI Stock Analysis

• Market Cap: AU$77.73M
• Dividend Yield: N/A
• Average Volume (3M): 118.82K
• Price to Earnings (P/E): 690.0
• Beta (1Y): 1.24
• Revenue Growth: 17.82%
• EPS Growth: N/A
• Country: AU
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 112,658,325
• 10 Day Avg. Volume: 79,692
• 30 Day Avg. Volume: 118,816
• PEG Ratio: -6.86
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 1.65
• P/FCF Ratio: -132.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.85
• Price Target Upside: 54.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: AU$0.50 ▼(-9.09% Downside)

The overall stock score is primarily impacted by the company's financial performance and technical analysis. The financial performance shows stability in the balance sheet but significant challenges in profitability and cash flow. Technical analysis indicates bearish momentum with oversold conditions. The high P/E ratio suggests overvaluation, further weighing down the score. The absence of earnings call and corporate events data means these factors do not influence the score.

Positive Factors

Revenue Growth

Modest revenue growth indicates the company is expanding its market presence, which is crucial for long-term sustainability and competitiveness.

Strong Gross Profit Margin

A strong gross profit margin suggests efficient production and service delivery, providing a buffer against cost fluctuations and supporting profitability.

Low Financial Leverage

Low financial leverage reduces risk and enhances financial stability, allowing the company to invest in growth opportunities without significant debt burden.

Negative Factors

Profitability Challenges

Low profitability margins indicate challenges in converting revenue into profit, which can hinder long-term growth and shareholder returns.

Cash Flow Issues

Negative cash flow highlights difficulties in cash generation, potentially limiting the company's ability to fund operations and growth initiatives.

Deteriorating Cash Generation

Deteriorating cash generation capabilities can strain liquidity and affect the company's ability to sustain operations and invest in future growth.

Medical Developments International Limited Business Overview & Revenue Model

Company Description

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.

How the Company Makes Money

MVP generates revenue through the sale of its medical products, particularly the Penthrox® inhalation anesthetic, which is marketed to hospitals, clinics, and emergency medical services. The company has established key partnerships with healthcare distributors and medical organizations to expand its reach and market penetration. Additionally, MVP benefits from licensing agreements and collaborations with other pharmaceutical companies, enabling it to maximize its product offerings and leverage research and development efforts. The company also focuses on ongoing product innovation and regulatory approvals to tap into new markets and increase its revenue streams.

Medical Developments International Limited Financial Statement Overview

Summary

Medical Developments International Limited exhibits a mixed financial performance. While there is some revenue growth and a strong gross profit margin, profitability remains a significant challenge. The balance sheet is stable with low leverage, but cash flow issues are a major concern, indicating potential liquidity risks. The company needs to focus on improving profitability and cash flow management to enhance its financial health.

Income Statement

The company has shown a modest revenue growth rate of 2.63% in the latest year, indicating some positive momentum. However, profitability remains a concern with a very low net profit margin of 0.24% and an EBIT margin of 0.36%. The gross profit margin is relatively strong at 75.35%, suggesting efficient production or service delivery. Overall, while there are signs of revenue growth, the company struggles with profitability.

Balance Sheet

The balance sheet is relatively strong with a low debt-to-equity ratio of 0.036, indicating low financial leverage and risk. The return on equity is minimal at 0.17%, reflecting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a stable financial structure. Overall, the balance sheet shows financial stability but limited profitability.

Cash Flow

The cash flow situation is concerning, with negative operating cash flow and free cash flow. The free cash flow growth rate is significantly negative at -92.85%, indicating deteriorating cash generation capabilities. The free cash flow to net income ratio is high at 11.30, suggesting that cash flow issues are not aligned with reported net income. Overall, the cash flow statement highlights significant challenges in cash generation and management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	39.06M	39.06M	33.15M	32.34M	21.94M	25.27M
Gross Profit	29.43M	29.43M	24.37M	-2.52M	-3.06M	16.67M
EBITDA	1.67M	1.67M	-29.45M	-4.28M	-12.86M	-11.11M
Net Income	94.00K	94.00K	-40.99M	-5.61M	-12.41M	-12.56M
Balance Sheet
Total Assets	66.40M	66.40M	59.16M	109.49M	101.36M	100.17M
Cash, Cash Equivalents and Short-Term Investments	17.84M	17.84M	9.73M	24.66M	20.40M	36.28M
Total Debt	1.99M	1.99M	2.29M	2.56M	2.81M	3.05M
Total Liabilities	11.29M	11.29M	13.43M	28.17M	44.06M	31.87M
Stockholders Equity	55.10M	55.10M	45.73M	81.31M	57.30M	68.30M
Cash Flow
Free Cash Flow	-486.00K	-486.00K	-13.95M	-24.16M	-15.94M	-15.37M
Operating Cash Flow	-43.00K	-43.00K	-10.78M	-16.50M	-10.72M	-8.81M
Investing Cash Flow	-1.04M	-1.04M	-3.17M	-7.67M	-5.21M	-6.56M
Financing Cash Flow	8.68M	8.68M	-807.00K	28.06M	142.00K	36.12M

Medical Developments International Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Neutral. The current price of 0.55 is above the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.61, and below the 200-day MA of 0.60, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.86 is Neutral, neither overbought nor oversold. The STOCH value of 68.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$41.09M	11.48	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$77.73M	690.00	0.19%	―	17.82%	―
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
BOD	39 Underperform	AU$4.26M	16.00	―	―	69.59%	―
IDT	37 Underperform	AU$24.81M	-3.16	-35.58%	―	45.30%	-24.18%

Medical Developments International Limited Corporate Events

Director Increases Stake in Medical Developments International

Medical Developments International Limited announced a change in the director’s interest, with Director Russell Basser acquiring 40,000 fully paid ordinary shares, increasing his total holdings to 55,873 shares. This acquisition, conducted through an on-market trade, reflects a significant investment by the director, potentially indicating confidence in the company’s future prospects and stability, which may positively influence stakeholder perceptions.

Medical Developments International Releases 2025 AGM Recording

Medical Developments International Limited announced the availability of a recording of its 2025 Annual General Meeting. This release, authorized by the Board of Directors, provides stakeholders with insights into the company’s operations and strategic direction, potentially impacting its market positioning and stakeholder engagement.

Medical Developments International Limited Successfully Concludes 2025 AGM

Medical Developments International Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried out successfully by poll. The outcomes indicate strong shareholder support for the company’s current direction, which may positively impact its future operations and industry positioning.

MVP Announces Leadership Transition and Reports Financial Growth at 2025 AGM

At the 2025 Annual General Meeting, MVP’s Chair, Gordon Naylor, announced his departure with Mark Fladrich set to assume the role in December. The company reported a significant improvement in its financials for FY25, with an 18% increase in revenue and a modest net profit after tax. MVP plans to deploy recently raised funds to support its growth strategy, while also enhancing governance and management systems. The transition in leadership is expected to bring fresh perspectives, crucial for the company’s continued growth.

Medical Developments International Reports Strong Q1 FY26 Performance

Medical Developments International Limited reported a strong financial performance for Q1 FY26, with a $1.9 million increase in Penthrox revenue and a 26% growth in its Australian hospital segment. The company is progressing with approvals for the Penthrox paediatric label in Europe, aiming to expand its market. Despite seasonal softness in its respiratory segment, MVP has managed to improve cash from operating activities and maintain a healthy cash balance of $16.1 million. The company plans to invest in growth initiatives to solidify Penthrox as a standard of care, which may result in softer short-term earnings but is expected to enhance long-term financial performance.

Director’s Share Acquisition at Medical Developments International

Medical Developments International Limited announced a change in the director’s interest, with Director Mark Fladrich acquiring 62,858 fully paid ordinary shares on the market as of September 30, 2025. This acquisition reflects a strategic move that could impact the company’s market positioning and stakeholder interests, highlighting the director’s confidence in the company’s future prospects.

Director Increases Stake in Medical Developments International

Medical Developments International Limited announced a change in the director’s interest, with Director Paul Townsend acquiring 25,000 fully paid ordinary shares on the market, valued at $16,785.31. This acquisition reflects an increase in the director’s stake in the company, potentially indicating confidence in the company’s future performance and impacting stakeholder perceptions positively.

Medical Developments International Appoints New Board Chair

Medical Developments International Limited announced the appointment of Mr. Mark Fladrich as the new Chair of the Board, effective December 1, 2025, succeeding Mr. Gordon Naylor. Mr. Fladrich, with over 30 years of experience in the pharmaceutical industry, is expected to bring significant commercial and strategic expertise to the company, particularly in pain management. This leadership transition is anticipated to strengthen MVP’s market position and support the company’s strategic objectives, including the growth of Penthrox. Additionally, the Board has created a Deputy Chair role, appointing Mr. Paul Townsend, to further enhance governance.

Medical Developments International Reports Strong FY25 Performance

Medical Developments International Limited reported a significant improvement in financial performance for the fiscal year ending June 30, 2025, with an 18% increase in revenue and a modest net profit after tax. The company successfully raised funds to support its growth strategy and plans to deploy these resources strategically in the coming year. The maturation of governance and management systems has led to measurable improvements, and the company expresses gratitude to its employees and shareholders for their support during challenging times.

Medical Developments International Announces 2025 AGM Details

Medical Developments International Limited has announced its 2025 Annual General Meeting, scheduled for October 10, 2025, at 1 pm AEDT. The meeting will be conducted in a hybrid format, allowing both in-person and virtual attendance via the Computershare platform. Shareholders are encouraged to submit proxy forms as per the instructions provided. This approach reflects the company’s commitment to accessibility and engagement with its stakeholders, potentially impacting shareholder participation and company transparency.